[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Barbara Ann Karmanos Cancer Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":426},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,40,66,93,114,135,156,176,196,219,242,266,289,313,337,359,381,403],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100560359","gemcitabine-nab-paclitaxel-plus-the-therabionic-p1-an-amplitude-modulated-radiofrequency-electromagnetic-fields-device-to-treat-metastatic-pancreatic-cancer-100560359",false,"NCT06576115","Gemcitabine, Nab-paclitaxel Plus the TheraBionic P1 (an Amplitude-Modulated Radiofrequency Electromagnetic Fields) Device to Treat Metastatic Pancreatic Cancer","Treatment of Patients With Metastatic Pancreatic Cancer With Gemcitabine and Nab-Paclitaxel and Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF)","Inclusion Criteria:\n\n* Patients must have histologically or cytologically proven advanced metastatic adenocarcinoma of the pancreas. Patients with mixed tumor with predominant adenocarcinoma pathology can be enrolled.\n* One or more measurable metastatic tumors per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) on imaging studies CT or MRI or PET scans\n* If female patient is of childbearing potential must have a negative serum pregnancy test (βhCG) documented up to 48 hrs prior to administration of chemotherapy.\n* Females of childbearing potential and males with female partners of childbearing potential, if sexually active, must agree to use two forms of contraception during the period of administration of study drug and up to 6 months after the end of treatment. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.\n* Age above 18 years\n* Based on prior studies, patients 80 years of age and older are considered to be at higher risk for fatal neutropenic sepsis. These patients should be thoroughly evaluated including geriatric assessment prior to enrollment. Clinical judgment should be exercised regarding patients' susceptibility for sepsis or infection (presence of biliary tract infection, uncontrolled diabetes, etc.). The patients in this age group should be not enrolled should there be any concern for rapid deterioration of clinical and functional status.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Parameter Levels:\n\nAbsolute neutrophil count (ANC) ≥ 1,500\u002FmcL Platelets \\> 100,000\u002FmcL Total bilirubin ≤ 1.5 X institutional upper limit of normal AST(SGOT)\u002FALT(SGPT) \\\u003C 2.5 X ins Creatinine ≤ 1.5 X institutional upper limit of normal Or CrCL \\> 50\n\n* Ability to understand and the willingness to sign an IRB-approved informed consent document (either directly or via a legally authorized representative).\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy with gemcitabine and\u002For nab-paclitaxel within six months prior to entering the study in the adjuvant or neo-adjuvant setting.\n* Patients receiving any other investigational agents.\n* Patients with known brain metastases are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events.\n* History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to gemcitabine and nab-paclitaxel.\n* No history of malignancy in last 3 years except cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer, who are considered to be eligible.\n* Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels such as amlodipine, nifedipine, ethosuximide are not allowed in the study unless their medical treatment is modified to exclude calcium channel blockers prior to enrollment. (Refer to Appendix D for a comprehensive list of excluded medications)\n* Patients with active and uncontrolled bacterial, viral or fungal infection requiring systemic therapy. Patients can be reevaluated for the study if the infection is deemed to be under control and the systemic therapy is completed.\n* Uncontrolled intercurrent illness including, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements or could compromise patients' safety.\n* Patient with known diagnosis of interstitial lung disease, sarcoidosis, pulmonary fibrosis or pneumonitis.\n* Pregnant women are excluded from this study because of potential risk for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy and AM RF EMF, patients who are breastfeeding will be excluded to participate in this study.\n* Patient has localized resectable or locally advanced tumor.\n* Patients has undergone major surgery, other than diagnostic surgery or procedures, within 4 weeks prior to the treatment day.\n* Patients is unable to comply with study procedures or anticipating a situation that would result in a treatment break for 14 or more consecutive days after the start of the study.\n* Patient is enrolled in any other clinical interventional trial.","ALL","18 Years",{"count":19,"type":20},30,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The goal of this study is to learn if the combination of nab-paclitaxel, gemcitabine and an Amplitude-Modulated Radiofrequency Electromagnetic Fields device (Therabionic P1) is safe and effective for patients with adenocarcinoma of the pancreas.",[26],"Metastatic Pancreatic Adenocarcinoma","RECRUITING","2026-08-05",{"date":30,"type":31},"2026-08-10","ACTUAL",{"date":33,"type":31},"2025-02-28",{"date":35,"type":20},"2027-07",{"name":37,"class":38},"Barbara Ann Karmanos Cancer Institute","OTHER",7,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":50,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100619336","ask-questions-about-clinical-trials-100619336","NCT07343297","Ask Questions About Clinical Trials","Ask Questions About Clinical Trials (ASQ - CT): An Implementation Trial of a Communication Intervention to Improve Patient-Provider Communication About Clinical Trials and Provider Invitations to Clinical Trials","ASQ-CT","Inclusion Criteria:\n\n* Age \\> or equal to 18 years\n* Appointment to see a provider at a Karmanos Cancer Institute-McLaren or a medical encounter at McLaren Center for Research and Innovation (MCRI) site for medical\u002Fsystemic treatment\n* Potentially eligible for a clinical trial\n* Speak and read English well enough to be able to understand consent documents and complete surveys\n\nExclusion Criteria:\n\n* Not able to complete study documents on their own physically or cognitively",{"count":49,"type":20},293,[51],"NA","The overall goal of this study is to assess the implementation of the Ask Questions about Clinical Trials (ASQ-CT) brochure, a patient-focused communication tool previously demonstrated to improve patient-provider communication about clinical trials. Participants will be given the ASQ-CT brochure at Time 1 (baseline) and participants will complete a questionnaire at three timepoints, baseline (Time 1), Pre-Research Visit (Time 2), and Post-Research Visit (Time 3).",[54,55,56],"Oncology","Cardiac Disease","Neurologic Disorder","2026-08-04",{"date":59,"type":31},"2026-08-06",{"date":61,"type":20},"2026-12-30",{"date":63,"type":20},"2028-04-05",{"name":37,"class":38},8,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":21,"phases":76,"briefSummary":78,"conditions":79,"keywords":81,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100649988","phase-1-impact-of-duffy-null-associated-neutropenia-on-chemotherapy-dosing-100649988","NCT07743086","Impact of Duffy-null Associated Neutropenia on Chemotherapy Dosing","A Prospective Study of Duffy-null Associated Absolute Neutropenia and Its Impact on Chemotherapy Dosing","Inclusion Criteria:\n\n* Participant must self-identify as being of Middle Eastern or African descent.\n* Participant must be diagnosed with histologically or cytologically confirmed solid organ cancer and be treatment naive.\n\n  * Melanoma is allowed; sarcoma is not eligible.\n  * Secondary malignancies are allowed.\n  * Participants who have received only surgery alone as treatment are eligible\n* Participant must be between the ages of 18-80.\n* Participant or their legally authorized representative (LAR) must be able to understand a written informed consent document and be willing to sign it.\n\nExclusion Criteria:\n\n* Participants with active and uncontrolled bacterial, viral, or fungal infection requiring IV antibiotics.\n\n  • Participants may be eligible for the study if the infection is deemed to be under control per investigator's discretion.\n* Participants who have ever received cytotoxic chemotherapy.\n\n  • Those who have already started a chemotherapy regimen with moderate likelihood of developing neutropenia will be considered for enrollment at the principal investigator's discretion.\n* Participants who are receiving concurrent chemo-radiation treatment.\n* Participants who are taking any other investigational drugs.\n* Participants who are pregnant or breastfeeding.\n* Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to follow the treatment plan.","80 Years",{"count":75,"type":20},886,[77,23],"PHASE1","The goal of this clinical trial is to:\n\n* In Phase 1 (observational) to develop an algorithm for treatment of Duffy-null positive patients for chemotherapy dosing\n* In Phase 2 (interventional), use the algorithm created in phase 1 to adjust chemotherapy dosing for Duffy-null patients",[80],"Solid Tumor Cancer",[82],"Duffy-null","NOT_YET_RECRUITING","2026-07-29",{"date":86,"type":31},"2026-08-03",{"date":88,"type":20},"2026-09",{"date":90,"type":20},"2029-04-30",{"name":37,"class":38},1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":111,"leadSponsor":113,"locationsCount":92},"100649674","phase-2-positron-emission-tomographycomputed-tomography-petct-imaging-in-patients-diagnosed-with-a-glioma-100649674","NCT07735819","Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT) Imaging in Patients Diagnosed With a Glioma","Tryptophan-kynurenine Pathway PET Imaging in Human Gliomas","FOR ARMS 1-3\n\nInclusion Criteria:\n\n* Age =18 years.\n* Patient is able to lie in the PET\u002FCT scanner for at least 60 minutes while undergoing scanning.\n* Patient is willing and able to review, understand, and provide written consent for the study procedures and indicates that they are aware of the investigational nature of this study.\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating are excluded. Premenopausal women (defined per institutional guidelines) must have a negative pregnancy test (urine or serum) within 7 days of the PET scan.\n* Severe increased intracranial pressure, status epilepticus, or other severe or progressing clinical symptoms requiring urgent intervention in the opinion of the treating\n* Karnofsky performance score \\\u003C60, as determined by one of the clinician co- investigators.\n\nADDITIONAL CRITERIA FOR ARM 1:\n\nInclusion Criteria:\n\n* Histopathology\u002Fcytopathological diagnosis of a glioblastoma without a history of radiation.\n* The tumor is deemed amenable for radiation treatment (pre-radiation planning MRI can be done before or after the PET scan).\n\nADDITIONAL CRITERIA FOR ARM 2:\n\nInclusion Criteria:\n\n* Previous histopathology\u002Fcytopathological diagnosis of glioblastoma.\n* History of glioma radiation.\n* Presence of a new or progressing enhancing brain lesion on follow-up clinical MRI suspicious for post-radiation glioma progression or late radiation-induced MRI changes (i.e., radiation injury), at least 7 mm in bidirectional diameter.\n* The most recent MRI, used for comparison with the PET\u002FCT, is performed within 4 weeks of the planned PET scan.\n\nADDITIONAL CRITERIA FOR ARM 3\n\nInclusion Criteria:\n\n* MRI diagnosis of a brain tumor, previously verified to be a low-grade (WHO grade 2, IDH (isocitrate dehydrogenase) mutant glioma, based on histopathology from biopsy or resection.\n* The detected mass on the most recent clinical MRI is at least 7 mm in bidirectional diameter (i.e., twice the PET scanner resolution).\n* The tumor does not require urgent (within 1 month) resection, steroid treatment, or radiation.\n* The most recent MRI, used for comparison with the PET\u002FCT, is performed within 4 weeks.\n* Patient agrees to have a baseline and follow-up PET\u002FCT scan (approximately 1 month later) and interval oral treatment with 200mg\u002Fday minocycline.\n* Due to planned minocycline treatment, patients will need to have adequate renal function\n\nExclusion Criteria:\n\n* Active connective tissue disorders, such as lupus or scleroderma.\n* History of allergic reaction to minocycline or any tetracyclines.\n* Ongoing treatment with warfarin with INR \\> 1.5.\n* History of colitis during antibiotics treatment.",{"count":101,"type":20},61,[23],"The goal of this clinical trial is to evaluate Positron emission tomography\u002Fcomputed tomography (PET\u002FCT) imaging with the radiotracer 1-(2-\\[18F\\]fluoroethyl)-l-tryptophan (\\[18F\\]FETrp) in patients diagnosed with a glioma. This study has 3 aims:\n\n* to assess if the \\[18F\\]FETrp PET\u002FCT can outperform Magnetic Resonance Imaging (MRI) by providing a better treatment target volume in newly diagnosed Stage 4 glioma patients\n* better differentiate tumor progression from radiation induced MRI changes in post treatment stage 4 gliomas\n* by giving a drug that can inhibit a pathway to allow objective assessment of treatment effects in low grade gliomas",[105,106],"Low Grade Glioma","Glioblastoma","2026-07-24",{"date":109,"type":31},"2026-07-30",{"date":88,"type":20},{"date":112,"type":20},"2031-06-30",{"name":37,"class":38},{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},"100600500","phase-1-metformin-combined-with-chemotherapy-andor-immunotherapy-in-solid-malignancies-100600500","NCT07098299","Metformin Combined With Chemotherapy and\u002For Immunotherapy in Solid Malignancies","A Phase I Dose-escalation and Metabolomics Study of Metformin Combined With Chemotherapy and\u002For Immunotherapy in Solid Malignancies","Inclusion Criteria:\n\n* Have histologically confirmed advanced solid tumor and are considered a suitable candidate for chemotherapy and\u002For immunotherapy or both\n* Are a male or female participant aged ≥ 18 years\n* Have provided a signed, written informed consent form\n* Have measurable disease per RECIST v1.1\n* Have adequate hematologic, renal, liver, and coagulation function as defined by the following:\n\n  1. Hemoglobin ≥ 8 g\u002FdL if determined suitable by the investigator for the selected chemotherapy and\u002For immunotherapy regimen for the particular patient\n  2. Absolute neutrophil count (ANC) \\> 1500\u002Fmm3\n  3. Platelets \\> 75,000\u002Fmm3 if determined suitable by the investigator for the selected chemotherapy and \u002For immunotherapy regimen for the particular patient\n  4. Estimated Glomerular Filtration Rate (eGFR) \\> 45 mL\u002Fmin\u002F1.73 m2 (as described by the Chronic Kidney Disease Epidemiology Collaboration \\[CKD-EPI\\] 2021 equation)\n  5. Total bilirubin ≤ 1.5 x upper limit of normal (ULN). Participants with known Gilbert's syndrome who have total bilirubin level ≤ 3 x ULN may be enrolled if deemed suitable for a particular patient by the investigator for the selected chemotherapy and\u002For immunotherapy regimen.\n  6. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \\\u003C 2.5 x ULN. For participants with hepatic metastases, AST and ALT ≤ 5 x ULN.\n  7. Alkaline phosphatase (ALP) \\\u003C 2.5 x ULN. For participants with hepatic and\u002For bone metastases ≤ 5 x ULN\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2, and suitable for chemotherapy\u002FIO recommended by the investigator.\n* Participants who have experienced expected toxicity from Cycle 1 of anticancer therapy which is unlikely to recover to grade 1 or better prior to Cycle 2 (e.g., anemia, alopecia, vitiligo, endocrine dysfunction associated with IO) and may otherwise not impact the eligibility will be allowed.\n* Women of child-bearing potential must agree to avoid becoming pregnant and male participants should avoid impregnating a female partner or donating sperm starting at initiation of treatment up until at least 90 days after the last dose of study drug.\n* Have an estimated life expectancy of at least 12 weeks\n\nExclusion Criteria:\n\n* Patients who have or are any of the following exclusion criteria are not eligible for participation in the study.\n* Patients with uncontrolled diabetes\n* Patients who have received metformin must be at least five half-lives beyond such treatment (four weeks) and must not be taking metformin at the time of enrollment.\n* Patients with a known hypersensitivity to metformin, its excipients, its analogs, or any of its components\n* Patients on other antidiabetic medicines are eligible as long as adding metformin will not be contraindicated\n* Patients with an inability to tolerate oral medications\n* Women who are pregnant or lactating\n* Patients with clinically significant intercurrent disease including, but not limited to:\n\n  1. New York Heart Association Class III or IV heart failure\n  2. Myocardial infarction, unstable angina, or stroke ≤ 3 months prior to Cycle 1 Day 1\n  3. Uncontrolled arrhythmia\n  4. Clinically significant active infection requiring IV antibiotic, antiviral, or antifungal medications\n* Patients with other current medical or other conditions that, in the opinion of the investigator, may confound study interpretation or prevent completion of study procedures and follow-up examinations\n* Patients with an unwillingness or inability to comply with the study procedures required in this protocol\n* Patients using an investigational agent within four weeks of study entry\n* Patients with uncontrolled metabolic disorders or primary or secondary effects of cancer that induce a high medical risk",{"count":122,"type":20},60,[77],"The goal of this clinical trial is to evaluate the safety of Metformin alone and in combination with chemotherapy or immunotherapy in patients with solid tumor cancers. The main questions it aims to answer are:\n\n* what are the toxicities of metformin at multiple dose levels\n* what is the maximum tolerated dose of Metformin in combination with chemotherapy or immunotherapy\n\nParticipants enrolled will be treated with standard of care chemotherapy and\u002For immunotherapy in accordance to their disease\u002Fstage. In addition, participants will take Metformin alone for 14 days in between the first cycle of chemotherapy and the second cycle of chemotherapy to determine tolerability to the Metformin. Participants will then take Metformin daily in combination with the standard of care chemotherapy and\u002For Immunotherapy from cycle 2 onwards.",[126],"Advanced Solid Tumor","2026-07-23",{"date":107,"type":31},{"date":130,"type":31},"2025-09-18",{"date":132,"type":20},"2028-07-07",{"name":37,"class":38},10,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":21,"phases":144,"briefSummary":145,"conditions":146,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":92},"100548374","phase-2-dapagliflozin-in-renal-al-amyloidosis-floral-100548374","NCT06420167","DapagliFLOzin in Renal AL Amyloidosis (FLORAL)","FLORAL","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with study procedures, including remote telehealth consultations with the study team, confirming availability, and agreeing to use mobile\u002Fweb applications for study purposes.\n* Age ≥18 years.\n* Histopathologic diagnosis of renal AL amyloidosis confirmed by biopsy of any tissue and evidence of \\>1.0 g\u002Fday proteinuria without any other identifiable cause.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2.\n* Plateau in any renal response (i.e., reduction in proteinuria) for at least 3 months prior to enrollment, as determined by the enrolling physician.\n* Residence in the state of Michigan.\n\nExclusion Criteria:\n\n* Either ongoing first line induction with anti-plasma cell therapy or ongoing post- induction maintenance for \\\u003C6 months prior to enrollment.\n* Diagnosis of symptomatic multiple myeloma, including presence of lytic bone disease, plasmacytomas, ≥60% plasma cells in the bone marrow, or hypercalcemia, either currently or in the past.\n* Women of child-bearing potential (i.e., those who have not undergone chemical or surgical sterilization or are not postmenopausal) and who are unwilling to use a medically accepted and reliable form of contraception while participating in the study and for 2 weeks following the last dose of study medication, as determined by the investigator, or have a positive pregnancy test at the time of enrolment or are currently breastfeeding.\n* Known allergic reactions to components of the dapagliflozin.\n* Treatment requiring type 1 or type 2 diabetes mellitus.\n* Baseline eGFR \\\u003C25 mL\u002Fmin\u002F1.73m2.\n* Acute or chronic liver disease with severe impairment of liver function (e.g., ascites, esophageal varices or coagulopathy)\n* Current or previous use of any SGLT2i.\n* Initiation or dose modification of angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) \\\u003C3 months prior to enrollment.\n* Active malignancy requiring treatment (other than AL amyloidosis and non-melanoma skin cancers).",{"count":143,"type":20},20,[23],"The goal of this clinical trial is to learn if an oral drug called dapagliflozin is safe and can reduce high protein levels in the urine of patients with renal amyloid light-chain (AL) amyloidosis using a decentralized study design.\n\nParticipants will be:\n\n* screened for the trial via an online platform\n* contacted by study personal to obtain electronic consent\n* enrolled in the trial if eligible and consented\n* contacted by study personal for further instructions and directions\n* sent dapagliflozin oral medication (supplied by the site pharmacy)\n* followed up regularly with the study team via telemedicine or other online avenues\n* monitored using lab work, inquiries about side effects and assessment of protocol adherence at 1 month, 3 months and 6 months\n* continue treatment for 6 months",[147],"Renal AL Amyloidosis","2026-06-23",{"date":150,"type":31},"2026-06-26",{"date":152,"type":31},"2024-07-11",{"date":154,"type":20},"2028-04",{"name":37,"class":38},{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":21,"phases":165,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":175},"100524362","phase-2-iberdomide-and-daratumumab-as-maintenance-therapy-after-an-autologous-stem-cell-transplant-for-multiple-myeloma-100524362","NCT06107738","Iberdomide and Daratumumab as Maintenance Therapy After an Autologous Stem Cell Transplant for Multiple Myeloma","IBEX: Phase 2 Trial of Iberdomide + SQ Daratumumab as Post-Autologous Stem Cell Transplant Maintenance Therapy in Multiple Myeloma","IBEX","Inclusion Criteria:\n\n1. Multiple Myeloma patients who have received prior DARA-containing induction therapy and have attained at least a partial response.\n2. Patients who have completed Autologous Stem Cell Transplant (ASCT) 90-150 days prior to registration, without any post-ASCT therapy and without post-ASCT disease progression (according to IMWG criteria)\n3. Patients who are Minimal Residual Disease positive (MRD (+)) as measured by the ClonoSEQ assay using a sensitivity of 10-5, measured 90-150 days following ASCT.\n4. Prior DARA-containing induction therapy (at least 3 cycles), attaining at least a partial response.\n5. Completed ASCT within 90-150 days prior to registration, without any post-ASCT therapy and without evidence of post-ASCT disease progression (according to IMWG criteria)\n6. MRD (+) at the time of study enrollment using the clonoSEQ NGS (next-generation sequencing) assay. Patients with an M-spike of ≥ 0.5 g\u002FdL and\u002For an abnormal free light chain ratio (with an involved serum free light chain of ≥ 10 mg\u002FdL) at enrollment are considered MRD (+) and do not require baseline MRD testing if they have previously had this testing done with successful clonality assessment.\n7. ECOG (Eastern Cooperative Oncology Group) Performance Status \\\u003C\u002F= 2\n8. Adequate bone marrow function as evidenced by platelets \\>\u002F= 75,000\u002Fmm3, hemoglobin \\>\u002F= 8 g\u002FdL, and ANC (absolute neutrophil count) \\>\u002F= 1,000\u002Fmm3 within 28 days prior to registration. NOTE: transfusion to achieve the hemoglobin threshold IS permissible.\n9. Adequate hepatic function defined by the following within 28 days prior to registration: total bilirubin \\\u003C\u002F=1.5 x IULN (institutional upper limit of the norm, except in case of Gilbert's syndrome) AND AST (aspartate aminotransferase and ALT (aspartate transaminase) \\\u003C\u002F=3.0 x IULN\n10. Adequate renal function, as defined by creatinine clearance (CrCl) \\>\u002F= 30 mL\u002Fmin., as measured by a 24-hour urine collection or estimated by the Cockcroft and Gault formula within 28 days prior to registration.\n11. All ASCT-related toxicities must have recovered to \\\u003C\u002F=Grade 1 (except for alopecia, fatigue and amenorrhea) prior to registration\n12. Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy test with a sensitivity of at least 25 mIU (milli-International unit)\u002FmL within 10-14 days prior to registration. FCBP must agree to have a second pregnancy test within 24 hours prior to starting Cycle 1. Further, FCBP must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control: one highly effective method and one additional effective method AT THE SAME TIME, at least 7 days before starting IBER, during therapy, during dose interruptions and continuing for 28 days following discontinuation of Iberdomide and for 90 days following the discontinuation of daratumumab. FCBP must also agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 28 days after the last dose of iberdomide and for 90 days after the last dose of daratumumab. Reliable contraception is indicated even where there has been a history of infertility, unless due to hysterectomy. Females of reproductive potential should be referred to a qualified provider of contraceptive methods, if needed.\n13. Men must agree to use a latex condom during sexual contact with a FCBP, even if they have had a successful vasectomy, during the study treatment and for 90 days after the last dose of study treatment. They must also agree to not donate sperm during the study and for 90 days after either the last dose of iberdomide or the last dose of daratumumab.\n14. Must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.\n15. Age 18 yrs. old or greater\n\nExclusion Criteria:\n\n1. Active HIV, or HCV (defined as detectable viremia for any of these conditions).\n2. Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen\\[HBsAg\\]). Patients with resolved infection (i.e., patients who are HBsAg negative but positive for antibodies to hepatitis B core antigen \\[anti-HBc\\] and\u002For antibodies to hepatitis B surface antigen \\[anti-HBs\\]) must be screened using real-time PCR (polymerase chain reaction) measurement of hepatitis B virus (HBV) DNA levels. Those who are PCR positive will be excluded.\n\n   EXCEPTION: Patients with serologic findings suggestive of HBV vaccination (anti-HBs positivity as the only serologic marker) AND a known history of prior HBV vaccination, do not need to be tested for HBV DNA by PCR\n3. Unable to assess MRD status at entry or is MRD(-) at 10-5 threshold at entry\n4. Heart attack or stroke within 90 days of study enrollment\n5. Unable to tolerate required anti-thrombotic or anti-viral prophylaxis\n6. Major surgery within 28 days of enrollment\n7. Medical, neurologic, or psychiatric condition which renders patient unable to safely comply with study therapy and schedule requirements (including, but not limited to, unstable angina, New York Heart Association Class III-IV congestive heart failure, or uncontrolled cardiac arrhythmia)\n8. Intolerance of prior DARA therapy (requiring discontinuation of DARA previously due to toxicity)\n9. A history of malignancy (other than multiple myeloma) unless all treatment of that malignancy was completed at least 2 years before consent and the patient has no evidence of disease before the date of enrollment. Exceptions are squamous and basal cell carcinomas of the skin, carcinoma in situ of the cervix or breast, or other non-invasive lesion that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 3 years.\n10. Be exhibiting clinical signs of meningeal or central nervous system involvement due to multiple myeloma.\n11. Have known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) \\\u003C50% of predicted normal.\n12. Have known moderate or severe persistent asthma within the past 2 years (see Section 9.2.4), or current uncontrolled asthma of any classification. Note that patients who currently have controlled intermittent asthma or controlled mild persistent asthma are allowed in the study, provided that FEV1 is ≥50% of predicted normal.\n\n    Note: pursuant to exclusion criteria (k) and (l), FEV1 testing is required for patients with suspected COPD or asthma. Patients with FEV1 \\\u003C50% of predicted normal (or for patients ≥65 years of age, old FEV1 \\\u003C50% or diffusing capacity of the lung \\[DLCO\\] \\\u003C50%) on screening assessment must be excluded.\n13. Have any of the following:\n\n    1. Myocardial infarction within 6 months of enrollment, or an unstable or uncontrolled disease\u002Fcondition related to or affecting cardiac function (eg, unstable angina, congestive heart failure, New York Heart Association Class III-IV),\n    2. Uncontrolled cardiac arrhythmia\n14. Have known allergies, hypersensitivity, or intolerance to boron or mannitol, sorbitol, corticosteroids, monoclonal antibodies or human proteins, or their excipients (refer to the IB) or known sensitivity to lenalidomide, thalidomide, or pomalidomide.\n15. Be pregnant, or breast-feeding, or planning to become pregnant or breast-feed while enrolled in this study or within 90 days after the last dose of study treatment(s). Or, if male, planning to father a child while enrolled in this study or within 90 days after the last dose of study treatment(s).\n16. Prolongation of QT interval on screening ECG as defined by a QTc interval \\> 470 msec using Fridericia's QT correction formula.\n17. Use of strong inhibitors or inducers of CYP3A4, P-gp, or BCRP for at least 14 days or 5 half-lives (whichever is shorter) prior to initiating protocol therapy.",{"count":122,"type":20},[23],"The goal of this phase 2 clinical trial is to learn if patients with Multiple Myeloma who are minimal residual disease positive after initial therapy (including an autologous stem cell transplant \\[ASCT\\]) will benefit from maintenance therapy with Iberdomide and subcutaneous (SC) Daratumumab. The main questions it aims to answer are:\n\n* Assess if giving Iberdomide and the SC Daratumumab in the maintenance setting is an effective treatment and warrants further investigation in patients with residual disease\n* Is giving Iberdomide and SC Daratumumab maintenance post ASCT a safe option\n\nParticipants will:\n\n* provide informed consent and complete screening assessments for eligibility within 28 days of starting treatment\n* Screening assessments include specific laboratory tests, a medical history assessment and a physical examination (including temperature, pulse, blood pressure, respirations, height and weight), an assessment of your heart function, a breathing test, cancer imaging, a bone marrow biopsy, minimal residual disease testing (MRD) and a questionnaire\n* If eligible, patients will start treatment with Iberdomide (1.0 mg on day 1-21 of each 28 day cycle, with an increase to 1.3 mg on Cycle 4 if the 1.0 mg dose was tolerated, to a maximum of 26 cycles or progressive disease, whichever is first) and SC Daratumumab (1800 mg SC on days 1, 8, 15 and 22 of cycle 1 and 2, then 1800 mg SC on Day 1 and 15 of cycle 3-6 and 1800 mg SC on Day 1 for cycles 7-26 to a maximum of 26 cycles or progressive disease, whichever is first)\n* while receiving treatment on study, physical exams (including temperature, pulse, blood pressure, respirations, height and weight), toxicity assessments, laboratory assessments and questionnaires will be done at various times over the course of the 26 cycles\n* an MRD assessment is required at 6, 12 and 24 months after starting treatment\n* End of treatment will occur once 26 cycles are completed, or cancer has progressed whichever comes first. At that time, specific laboratory tests, a physical examination (including temperature, pulse, blood pressure, respirations, height and weight), cancer imaging, a bone marrow biopsy and minimal residual disease testing (MRD) will occur.",[168],"Multiple Myeloma",{"date":150,"type":31},{"date":171,"type":31},"2023-12-21",{"date":173,"type":20},"2028-12-31",{"name":37,"class":38},2,{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":184,"targetDuration":4,"studyType":21,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":92},"100495961","dietary-reporting-in-the-amyloidoses-100495961","NCT05738005","Dietary Reporting In The Amyloidoses","DRITA Pilot Trial: Dietary Reporting in the Amyloidoses","DRITA","Inclusion Criteria:\n\n* 18 years of age or older\n* Diagnosed with any type of amyloidosis\n* Speak, read and write in English\n* Willing to use the MyFitnessPal app on their own smartphone\n\nExclusion Criteria:\n\n* a planned autologous stem cell transplant or a solid organ transplant in the 12 weeks after enrollment\n* cognitive or perceptual disturbances",{"count":185,"type":20},40,[51],"The goal of this clinical trial is to learn about malnutrition and weight loss in patients with Amyloidosis.\n\nThe main question it aims to answer is:\n\nIs it feasible to use a low-cost nutrition-based application (apps) for use on a smartphone to obtain detailed information on caloric intake in Amyloidosis patients\n\nParticipants will be asked to:\n\n* Download the MyFitnessPal application on their smartphone and view an online tutorial\n* After a week of practice, from weeks 2-9, participants will enter daily dietary intake as well as daily herbal\u002Falternative supplement intake into the MyFitnessPal application on their smartphone.\n* complete a questionnaire prior to starting the application, after week 2 and at week 10 after starting the application",[189],"Amyloidosis",{"date":150,"type":31},{"date":192,"type":31},"2023-03-02",{"date":194,"type":20},"2028-11-21",{"name":37,"class":38},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":203,"minAge":204,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":21,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":217,"leadSponsor":218,"locationsCount":92},"100644767","study-of-the-therabionic-p1-device-in-patients-with-metastatic-triple-negative-breast-cancer-after-progression-100644767","NCT07672431","Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression","A Pilot Study of the Efficacy of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer in the Third-line Setting","Inclusion Criteria:\n\n* Participant must have histologically confirmed invasive breast cancer that is hormone receptor (HR) negative and Human Epidermal Growth Factor Receptor 2 (HER2) negative according to the American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (Estrogen Receptor (ER) and progesterone receptor (PR) \\\u003C 1% and HER2 negative by immuno-histochemistry (IHC) and\u002For fluorescent in situ hybridization \\[FISH\\]\n* Participant must have evaluable disease as defined by the investigator using CT, MRI, or positron emission tomography (PET) scan\n* Participant must have refractory disease and failed, not tolerated, or progressed on at least two lines of prior standard therapeutic regimens for mTNBC.\n\n  • Participant must have a washout period of at least 14 days between the last line of treatment and the start of study treatment.\n* Participant must be a woman of 22 years of age or older.\n* Participant must have a life expectancy of at least three months\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2\n* It is unknown what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of child-bearing potential must agree to avoid becoming pregnant and male participants should avoid impregnating a female partner and donating sperm starting at initiation of treatment up until at least 12 weeks after treatment discontinuation\n\n  * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy)\n  * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation.\n  * Agree to practice true abstinence from sexual intercourse when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence methods such as calendar, ovulation, symptothermal, or post ovulation tracking are not acceptable.\n  * Not in a sexual relationship in which they may become pregnant (i.e. same-sex relationship)\n  * If they are of child-bearing potential, agree to use at least one highly effective AND at least one additional method of contraception. Withdrawal is not an acceptable contraceptive method.\n\nExclusion Criteria:\n\n* Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints.\n* Participants with known untreated brain metastases will be excluded from this clinical trial. Stable brain metastases will be allowed, and it will be confirmed by stable brain magnetic resonance imaging (MRI) with and without contrast within 8 weeks of signing consent.\n* Participants who are taking any other investigational drugs\n* Participants who are pregnant or breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued\n* Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae).\n* Participants who plan to receive calcium channel blockers and any agent blocking L-type of T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, supplemental vitamin C\u002Fascorbic acid, etc.) unless their medical treatment is discontinued prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study\n* Participants who plan to receive anticancer therapy that blocks L-type or T-type voltage gated calcium channels (i.e., eribulin, rucaparib, or niraparib) as part of their third line treatment. Participants who have received eribulin, rucaparib, or niraparib as part of a previous line of therapy are eligible, provided there has been at least 14 days between the last date of treatment and the start of study treatment.\n* Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to follow the treatment plan\n* Participants with a known severe (e.g., anaphylactic) allergy to nickel","FEMALE","22 Years",{"count":206,"type":20},24,[51],"The goal of this clinical trial is to learn if adding the TheraBionic P1 device to standard of care third line treatment for adult women with metastatic triple negative breast cancer (mTNBC) who have failed, not tolerated, or progressed on standard first- and second-line treatment options can work better than the standard of care alone. The main questions it aims to answer is:\n\n* will the addition of the TheraBionic P1 device to standard of care third line treatment affect progression free and overall survival in these participants",[210],"Triple Negative Breast Cancer",[212],"mTNBC","2026-06-19",{"date":215,"type":31},"2026-06-29",{"date":88,"type":20},{"date":173,"type":20},{"name":37,"class":38},{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":4,"eligibilityCriteria":225,"healthyVolunteers":11,"sex":16,"minAge":226,"maxAge":227,"enrollmentInfo":228,"targetDuration":4,"studyType":21,"phases":230,"briefSummary":231,"conditions":232,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":236,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":92},"100626472","culturally-adapting-an-intervention-to-increase-genetic-testing-in-african-american-cancer-survivors-100626472","NCT07436078","Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors","A Community-Engaged Approach to Culturally Adapting an Intervention to Increase Uptake of Genetic Testing Among African American Cancer Survivors","Inclusion Criteria:\n\n* Participants enrolled in Detroit Research on Cancer Survivors (Detroit ROCS)\n* Diagnosis of Primary Breast, prostate, or colorectal cancer on or after 1\u002F1\u002F2013\n* have received or currently receiving care at Karmanos Cancer Institute\n* meet one or more of the National Comprehensive Cancer Network (NCCN) guidelines for cancer genetic testing as described below\n\nFemale breast\n\n1. personal diagnosis at age ≤50\n2. personal history of the triple-negative subtype\n3. at least 1 close (first- or second-degree) relative diagnosed with breast cancer at age \\\u003C50\n4. at least 1 close relative diagnosed with ovarian cancer\n5. 2+ close relatives diagnosed with breast or prostate cancer\n6. age \\\u003C50 AND another primary breast cancer at any age\n7. 2+ primary breast cancers at any age\n\nOR Prostate\n\n1. personal history of high-risk or very high-risk prostate cancer\n2. personal history of regional or metastatic prostate cancer\n3. personal history of less than high-risk prostate cancer with a suggestive family history (i.e., father or brother or multiple relatives with prostate cancer diagnosed at age \\\u003C60; at least 1 relative with breast, ovarian, or pancreatic cancer; or at least 1 relative with colorectal, ovarian, pancreatic, or kidney cancer)\n\nOR Colorectal\n\n1. personal diagnosis at age ≤50\n2. at least 1 close relative diagnosed with HNPCC at age \\\u003C50\n3. at least 2 close relatives diagnosed with an HNPCC cancer at any age\n4. colorectal and \\>=1 primary endometrial, ovarian, gastric, pancreatic, or prostate\n\nExclusion Criteria:\n\n* Previous genetic counseling and\u002For testing","20 Years","79 Years",{"count":229,"type":20},85,[51],"The goal of this clinical trial is to culturally adapt an educational genetic counseling intervention to increase the uptake in genetic counseling and testing among African Americans at risk for heredity cancers. With the help of community stakeholders and clinical genetic professionals the investigators will:\n\n* adapt and refine a culturally relevant online educational genetic counseling program for at-risk African Americans\n* Test the effects of the educational program\n* collaborate with community leaders and clinical genetic professionals to translate study findings, develop a road map for dissemination to the community, and identify barriers to prepare for future trials.\n\nParticipants from Detroit Research on Cancer Survivor group will be offered enrollment. Once consent is obtained, questionnaires will be completed before an online genetic counselling intervention immediately after, and at 3 months",[233,234,235],"Female Breast Cancer","Prostate Cancer","Colorectal Carcinoma",{"date":148,"type":31},{"date":238,"type":31},"2026-04-18",{"date":240,"type":20},"2029-07",{"name":37,"class":38},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":203,"minAge":204,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":21,"phases":250,"briefSummary":251,"conditions":252,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":258,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":65},"100609734","a-study-of-the-therabionic-p1-device-in-breast-cancer-100609734","NCT07218432","A Study of the TheraBionic P1 Device in Breast Cancer","A Window of Opportunity Pilot Study: TheraBionic P1 Device for Patients With Resectable Early-stage Breast Cancer in a Neoadjuvant Setting","Inclusion Criteria:\n\n* Participant must have histologically proven invasive breast cancer that is HR (hormone receptor) positive and HER2 (Human Epidermal Growth Factor Receptor 2) negative according to the 2010 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (ER and\u002For PR (progesterone receptor) \\>1% and HER2 negative by immunohistochemistry \\[IHC\\] and\u002For fluorescent in situ hybridization \\[FISH\\]).\n* Participant must have early-stage operable disease (stage I-II or III who have planned upfront surgery) and agree to definitive upfront surgery.\n* Participant must be available for at least two weeks of TheraBionic treatment prior to scheduled resection\n* Participant must have archival tissue available.\n* Participant must be a woman aged 22 years or older\n* Participant must be able to understand a written informed consent document and be willing to sign it\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* It is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of child-bearing potential must agree to avoid becoming pregnant starting at initiation of treatment up until at least 30 days after the last TheraBionic P1 session\n\nExclusion Criteria:\n\n* Participants that are receiving or will receive neoadjuvant chemotherapy or neoadjuvant hormonal therapy\n* Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints\n* Participants that are taking any other investigational drugs\n* Participants that are pregnant or breastfeeding due to the unknown but potential risk for adverse events. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued\n* Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae).\n* Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid\u002Fvitamin C, etc.) unless their medical treatment is discontinued at least one day prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study.\n* Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device\n* Participants with a known severe (e.g., anaphylactic) allergy to nickel.",{"count":206,"type":20},[51],"The goal of this clinical trial is to learn if adding cancer-specific amplitude-modulated radiofrequency electromagnetic field therapy (TheraBionic P1 device) to the treatment of resectable early-stage breast cancer will affect the pathological response.",[253,254,255,256,257],"Breast Cancer Stage I","Breast Cancer Stage II","Breast Cancer Stage IIIA","Hormone Receptor Positive Tumor","HER2-negative Breast Cancer","2026-04-16",{"date":260,"type":31},"2026-04-21",{"date":262,"type":20},"2026-10",{"date":264,"type":20},"2028-06-30",{"name":37,"class":38},{"id":267,"slug":268,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":272,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":204,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":287,"locationsCount":288},"100602030","therabionic-p1-device-in-subjects-with-advanced-hepatocellular-carcinoma-100602030","NCT07118202","TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma","TheraBionic P1 Device for Patients With Advanced Hepatocellular Carcinoma (HCC) Who Fail First and Second Line Therapy","TARGET-HCC","Inclusion Criteria:\n\n* Patients with advanced hepatocellular carcinoma (HCC) (defined as a liver tumor not eligible for local therapies given the extent of disease or a livor tumor that recurred after local therapy)\n* Patients who have failed at least two lines of therapy\\* or who are no longer eligible for any line of standard therapy or who are intolerant to at least two lines of therapy.\n* Patients with evaluable disease\n* Patients must be ≥ 22 years old and must be able to understand and sign an informed consent.\n* Female patients of childbearing potential and their partners and male patients must agree to use adequate contraception during the period of study treatment.\n* Patients with a life expectancy of at least 3 months\n\nExclusion Criteria:\n\n* Patients with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints\n* Patients taking any other investigational drugs\n* Patients with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of the device\n* Patients receiving calcium channel blockers and any agent blocking L-type of T-type Voltage Gated Calcium Channels, e.g., amlodipine, nifedipine, ethosuximide, ascorbic acid (vitamin C), etc. unless their medical treatment is discontinued to prior to treatment on study. Patients must agree to abstain from using calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels for the duration of treatment on study.\n* Patients who are breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued.\n* Patients that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device for the prescribed period and frequency (three 60-minute treatments in the morning, middle of the day, and evening)\n* Patients with a known severe (e.g., anaphylactic) allergy to nickel",{"count":275,"type":20},198,[51],"The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced hepatocellular carcinoma (HCC) who have no standard of care options can affect patients survival. The main questions it aims to answer are:\n\n* will the TheraBionic P1 device affect overall survival in advance HCC\n* the long term safety and tolerability of the TheraBionic P1 device\n* assessment of how the disease responded to the TheraBionic P1 device",[279],"Hepatocellular Carcinoma Recurrent","2026-04-07",{"date":282,"type":31},"2026-04-13",{"date":284,"type":31},"2025-10-20",{"date":286,"type":20},"2028-08-31",{"name":37,"class":38},6,{"id":290,"slug":291,"hasResults":11,"nctId":292,"briefTitle":293,"officialTitle":294,"acronym":4,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":296,"targetDuration":4,"studyType":21,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":92},"100482011","phase-1-f-tryptophan-petct-in-human-cancers-100482011","NCT05556473","F-Tryptophan PET\u002FCT in Human Cancers","A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET\u002FCT Imaging In Human Cancers","Inclusion Criteria:\n\n* Age ≥18 years.\n* Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.\n* Patient is able to lie in the PET\u002FCT scanner for at least 70 minutes while undergoing scanning.\n* Women of childbearing potential must not be pregnant or breastfeeding.\n* Recent anatomic imaging with visible disease (tumor) for comparison with the PET\u002FCT. .\n* Physical exam within 28 days of PET imaging, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST and ALT) within 14 days.\n* Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.\n\nInclusion Criteria Specific for Intracranial Tumors\n\n\\- Clinical and MRI diagnosis of an intracranial lesion suspicious for a brain tumor, including gliomas or metastatic brain tumors; primary, residual, or recurrent brain tumors (judged by clinical imaging) will qualify.\n\nInclusion Criteria Specific for Extracranial Neuroendocrine Tumors:\n\n* Histopathologically confirmed, well-differentiated metastatic neuroendocrine tumor.\n* ECOG performance status of 2 or better.\n* Patients receiving stable-dose somatostatin analogs (SSAs, long-acting release \\[LAR\\], depot) for \\>3 months before enrollment may be enrolled on the study, but such treatment is not required.\n\nInclusion Criteria specific for Extracranial Primary Breast tumors:\n\n* Clinical and radiological diagnosis of a breast cancer\n* ECOG performance status of 2 or better.\n\nInclusion Criteria specific for Rectal tumors:\n\n* Histologically confirmed colorectal cancer, which is located in the rectum.\n* ECOG performance status of 2 or better.\n\nExclusion Criteria:\n\n* Patients who are pregnant or lactating are excluded.\n\nExclusion Criteria Specific for Intracranial Tumors:\n\n* Severe increased intracranial pressure, status epilepticus, or other symptoms requiring emergency or urgent intervention.\n* Tumor surgery or radiation within 1 month prior to the PET scan\n\nExclusion Criteria Specific for Extracranial Neuroendocrine Tumors:\n\n* Tumor-directed therapy within 3 months to the area of planned imaging.\n* Ongoing treatment with a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide).\n* Use of telotristat ethyl (a tryptophan-hydroxylase inhibitor) within one month.\n\nExclusion Criteria for Extracranial Primary Breast tumors:\n\n-Recent (within 1 month) tumor resection or radio-chemotherapy (acute\u002Fsubacute post-treatment inflammatory changes may cause false positive increases on PET).\n\nExclusion Criteria for Rectal tumors:\n\n-Active inflammatory bowel disease (Crohn's or Ulcerative colitis) involving the rectum.",{"count":206,"type":20},[77],"Imaging procedures such as 1-(2-\\[18F\\]FLUOROETHYL)-L-Tryptophan PET\u002FCT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.",[300,301,302,303,304],"Intracranial Glioma","Metastatic Brain Tumor","Breast Cancer","Neuroendocrine Tumors","Rectal Cancer","2026-01-21",{"date":307,"type":31},"2026-01-23",{"date":309,"type":31},"2022-09-29",{"date":311,"type":20},"2027-12-31",{"name":37,"class":38},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":204,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":21,"phases":322,"briefSummary":323,"conditions":324,"keywords":327,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":4},"100610457","a-ph-ii-study-of-the-therabionic-p1-device-in-subjects-with-hormone-positive-breast-cancer-100610457","NCT07227831","A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer","A Phase 2 Study of TheraBionic P1 Device for Patients With Metastatic Hormone Positive Breast Cancer Post Endocrine Therapy","Inclusion Criteria:\n\n* Participant must have locally advanced\u002Funresectable or metastatic Hormone Receptor (HR) positive, Human Epidermal growth factor receptor 2 (HER2) negative breast cancer as defined by the 2010 American Society of Clinical Oncology (ASCO) College of American Pathologists (CAP) guidelines (estrogen receptor \\[ER\\] and\u002For progesterone receptor \\[PR\\] \\>1% and HER2 negative by immunohistochemistry \\[IHC\\] and\u002For fluorescent in situ hybridization \\[FISH\\]).\n* Participant must have received and progressed on or are intolerant to all therapies known to confer overall survival benefit, including at least one line of endocrine + CDK4\u002F6 inhibitor therapy AND one line of cytotoxic such as chemotherapy and\u002For antibody drug conjugates (ADCs).\n* Participant must be a woman ≥ 22 years old and must be able to understand and sign an informed consent form.\n* Participant must have a life expectancy of at least 3 months.\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.\n* it is not known what effects this treatment has on human pregnancy or development of the embryo or fetus. Therefore, women of childbearing potential must agree to avoid becoming pregnant starting at initiation of treatment up until at least 30 days after the last TheraBionic P1 session.\n* Participants must meet one of the following:\n\n  * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy)\n  * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation.\n  * Agree to practice true abstinence when this is in line with the preferred and usual lifestyle of the participant. Periodic abstinence methods such as calendar, ovulation, symptothermal, or post ovulation tracking are not acceptable.\n  * Not in a sexual relationship in which they may become pregnant (i.e. same-sex relationship)\n  * If they are of childbearing potential, agree to use at least one method of contraception. Withdrawal is not an acceptable contraceptive method.\n\nExclusion Criteria:\n\n* Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints\n* Participants that are taking any other investigational drugs.\n* Participants that are pregnant or breastfeeding. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued.\n* Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae).\n* Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid\u002Fvitamin C, etc.) unless their medical treatment is discontinued at least one day prior to treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study.\n* Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device.",{"count":321,"type":20},82,[51],"The goal of this clinical trial is to learn if the TheraBionic P1 device given to patients with advanced or metastatic HR positive, HER2 negative breast cancer who have progressed on standard of care options can affect patients survival. The main questions it aims to answer are:\n\n* will the TheraBionic P1 device affect progression free and overall survival in advanced or metastatic HR positive, HER2 negative breast cancer\n* the long term safety and tolerability of the TheraBionic P1 device\n* assessment of how the disease responded to the TheraBionic P1 device",[257,256,325,326],"Advanced Breast Cancer","Metastatic Breast Cancer",[328],"therabionic","2025-11-12",{"date":331,"type":31},"2025-11-13",{"date":333,"type":20},"2026-02",{"date":335,"type":20},"2028-05-22",{"name":37,"class":38},{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":16,"minAge":204,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":21,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":350,"lastUpdatePostDateStruct":351,"startDateStruct":353,"completionDateStruct":355,"leadSponsor":357,"locationsCount":358},"100603006","phase-2-amplitude-modulated-radiofrequency-electromagnetic-fields-am-rf-emf-in-combination-with-fruquintinib-in-refractory-metastatic-colorectal-cancer-100603006","NCT07130903","Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","A Phase 2 Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer","Inclusion Criteria:\n\n* Participant must have histologically or cytologically confirmed metastatic colorectal adenocarcinoma. There must be previous documentation of RAS (Rat sarcoma mutation), BRAF (B-Raf proto-oncogene, Serine\u002Fthreonine kinase), MSI\u002FMMR (microsatellite instability, mismatch repair) , and HER2 (Human epidermal growth factor receptor 2) status.\n* Participant must have progressed on or been intolerant to the following previous treatments (if not contraindicated):\n\n  * Fluoropyrimidine-, oxaliplatin-, or irinotecan-based chemotherapy\n  * Anti-VEGF (vascular endothelial growth factor) biological therapy, such as bevacizumab, aflibercept, or ramucirumab\n  * If RAS is wild type, an anti-EGFR (epidermal growth factor receptor) therapy like cetuximab or panitumumab\n* Participant must have evaluable disease as defined by the investigator using CT (computed tomography), MRI (magnetic resonance imaging), or PET (positron emission tomograph) scan.\n* Participant must have a body weight ≥ 40 kg.\n* Participant must be aged 22 years or older.\n* Participant must be able to understand a written informed consent document and be willing to sign it.\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n* Participant must have adequate organ and marrow function within 14 days prior to the initiation of treatment as described below:\n* Participant should have an expected lifespan of \\>12 weeks as determined by the investigator.\n* Fruquintinib is suspected to cause loss of human pregnancy and impaired development of the embryo or fetus. Therefore, women of child-bearing potential must agree to avoid becoming pregnant and male participants should avoid impregnating a female partner starting at initiation of treatment up until at least 14 days after the last fruquintinib dose.\n\nExclusion Criteria:\n\n* Participants with uncontrolled hypertension per investigator discretion.\n* Participants with a history or presence of gastric\u002Fduodenal ulcer or ulcerative colitis, hemorrhage of an unresected gastrointestinal tumor, perforation, fistulas, or any other condition that could, in the investigator's judgment, result in gastrointestinal hemorrhage or perforation.\n* Participants with a history or presence of hemorrhage from any other site (i.e., lower GI bleed, hemoptysis or hematemesis) within two months prior to screening.\n* Participants with a history of a thromboembolic event, including deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial embolism within three months prior to screening unless they are on a stable dose of anticoagulant and no further evidence of active thromboses are seen on CT scan or venous Doppler imaging. Participants with saddle (massive) pulmonary embolism that require thrombectomy\u002Fthrombolysis within 12 months of screening are excluded from the trial.\n* Participants with a history of stroke and\u002For transient ischemic attack within 12 months prior to screening.\n* Participants with clinically significant cardiovascular disease, including but not limited to acute myocardial infarction or coronary artery bypass surgery within six months prior to enrollment, severe or unstable angina pectoris, New York Heart Association Class III\u002FIV congestive heart failure, ventricular arrhythmias requiring treatment, or previous left ventricular ejection fraction (LVEF) \\\u003C 50% by echocardiogram.\n* Participants with corrected QT interval using the Fridericia method (QTcF) \\> 480 msec or any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age in a first-degree relative.\n* Participants taking concomitant medications with a known risk of causing QT prolongation and\u002For torsades de pointes. (Source list is continuously updated online at www.crediblemeds.org.)\n* Participants taking systemic anti-neoplastic therapies four weeks prior to the first dose of study drug, including chemotherapy, biotherapy, or immunotherapy. Palliative radiation is allowed if it does not cover all evaluable disease.\n* Participants taking systemic small molecule targeted therapies (e.g., tyrosine kinase inhibitors) within five half-lives or four weeks, whichever is shorter, prior to the first dose of study drug.\n* Participants who have undergone major surgery within 30 days prior to the first dose of study drug or if they still have unhealed surgical incision from previous surgery.\n* Participants with any unresolved toxicities from a previous antitumor treatment greater than NCI CTCAE v5.0 grade 2.\n* Participants that have current drug or alcohol abuse.\n* Participants with known human immunodeficiency virus (HIV) infection are not eligible if their viral load and\u002For CD4 (cluster of differentiation 4) count are considered poorly controlled with anti-HIV therapy.\n* Participants with a known history of active viral hepatitis. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Participants that test positive for hepatitis C virus (HCV) but are currently being treated are eligible if they have an undetectable HCV viral load.\n* Participants with clinically uncontrolled active infections requiring intravenous antibiotics.\n* Participants with tumor invasion of a large vascular structure (e.g., pulmonary artery, superior or inferior vena cava).\n* Participants with brain metastases and\u002For spinal cord compression untreated with surgery and\u002For radiotherapy and without clinical imaging evidence of stable disease for 14 days or longer.\n* Participants with known active secondary malignancy, unless, in the opinion of the investigator, it is unlikely to interfere with the safety and efficacy of the endpoints.\n* Participants that are unable to take medication orally including those with dysphagia or an active gastric ulcer resulting from previous surgery (e.g., gastric bypass) or severe gastrointestinal disease, or any other condition that the investigator believes may affect absorption of fruquintinib.\n* Participants with metabolic disorder that the investigator suspects may prohibit fruquintinib action, affect interpretation of study results, or put the participant at undue risk of harm based on the investigator's assessment.\n* Participants that have received prior fruquintinib treatment.\n* Participants with a known hypersensitivity to fruquintinib or any of its inactive ingredients including the azo dyes tartrazine, FD\\&C yellow 5, and sunset yellow FCF.\n* Participants taking strong inducers or inhibitors of CYP3A4 within five half-lives or four weeks, whichever is longer, before the first dose of study drug. Refer to Appendix 2 for a comprehensive list of excluded medications related to CYP3A4.\n* Participants that are taking any other investigational drugs.\n* Participants with active oral mucosal inflammation, ulceration, or other pathology that could interfere with the use of TheraBionic P1 device (for example: mucositis, thrush, bleeding mucosal lesions, oral herpes, aphthous stomatitis, mouth ulcers, chancre sores, gingivostomatitis, herpangina, aphthae).\n* Participants receiving calcium channel blockers and any agent blocking L-type or T-type voltage gated calcium channels (for example: amlodipine, nifedipine, ethosuximide, ascorbic acid\u002Fvitamin C, etc.) unless these drugs are discontinued at least 7 days prior to starting TheraBionic P1 device treatment. Participant must agree to abstain from using calcium channel blockers for the duration of treatment on study. Refer to Appendix 3 for a comprehensive list of excluded medications related to calcium channels.\n* Participants that are pregnant or breastfeeding are ineligible for this study. If a breastfeeding participant would like to be part of this study, breastfeeding must be discontinued.\n* Participants who have received a live vaccine ≤ 28 days before the first dose of fruquintinib. (Seasonal vaccines for influenza are generally inactivated vaccines and are allowed. Intranasal vaccines are live vaccines and are not allowed.)\n* Participants that do not agree to be followed according to the study protocol or have cognitive or physical inability to use the device.",{"count":345,"type":20},102,[23],"The goal of this clinical trial is to learn if adding amplitude-modulated radiofrequency electromagnetic fields (AM RF EMF) to Fruquintinib in metastatic colorectal cancer that has not responded to other standard treatment is:\n\n* Effective in improving survival\n* safe and tolerable",[349],"Metastatic Colorectal Adenocarcinoma","2025-11-05",{"date":352,"type":31},"2025-11-10",{"date":354,"type":31},"2025-09-10",{"date":356,"type":20},"2030-04-17",{"name":37,"class":38},9,{"id":360,"slug":361,"hasResults":11,"nctId":362,"briefTitle":363,"officialTitle":364,"acronym":365,"eligibilityCriteria":366,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":367,"targetDuration":4,"studyType":21,"phases":369,"briefSummary":370,"conditions":371,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":373,"lastUpdatePostDateStruct":374,"startDateStruct":376,"completionDateStruct":378,"leadSponsor":380,"locationsCount":92},"100343387","capable-crossfit-and-physical-activity-a-better-life-experience-100343387","NCT03750981","C.A.P.A.B.L.E. (CrossFit® and Physical Activity: A Better Life Experience)","Does High-Intensity Functional Training Improve Patient Movement and Quality of Life? A Study of CrossFit® in Cancer Survivors","CAPABLE","Inclusion Criteria:\n\n* Aged 18 years or older at time of program recruitment\n* Diagnosed with any cancer\n* Cleared from their physician to participate in the program (We assume that most patients will have completed treatment, however if a patient is currently under treatment, this should be their oncologist. If the patient is not currently undergoing treatment, this could be primary care physician or oncologist).\n* Available transportation to and from the facility on session days\n\nExclusion Criteria\n\n* Widely metastatic cancers to the brain or bone may be excluded.\n* Patients using mobility assistance devices may be excluded. Exclusionary criteria will be reviewed on a case-by-case basis and patients with these limitations may be included with approval from Dr. Beebe-Dimmer and the referring physician.",{"count":368,"type":20},500,[51],"This study will introduce cancer survivors to cross-training with the expectation that the program proposed will ultimately result in superior improvements in functional performance, body composition and quality of life compared with the current American Cancer Society (ACS) guidelines for cancer survivors.",[372],"Cancer Survivors","2025-11-04",{"date":375,"type":31},"2025-11-06",{"date":377,"type":31},"2018-11-12",{"date":379,"type":20},"2028-11-30",{"name":37,"class":38},{"id":382,"slug":383,"hasResults":11,"nctId":384,"briefTitle":385,"officialTitle":386,"acronym":4,"eligibilityCriteria":387,"healthyVolunteers":11,"sex":203,"minAge":17,"maxAge":4,"enrollmentInfo":388,"targetDuration":4,"studyType":21,"phases":389,"briefSummary":390,"conditions":391,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":396,"lastUpdatePostDateStruct":397,"startDateStruct":398,"completionDateStruct":400,"leadSponsor":402,"locationsCount":92},"100600255","a-study-of-disappearing-markers-for-daily-radiation-treatment-delivery-for-breast-cancer-patients-100600255","NCT07095114","A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.","A Phase I\u002FII Study of Disappearing Markers for Daily Radiation Treatment Delivery","Inclusion Criteria:\n\n* Participant must have histologically or cytologically confirmed stage 0 ductal carcinoma in situ (DCIS), I, II or III breast cancer and be planning to undergo radiation therapy (RT) after surgery\n* Participants must be 18 years of age or older\n* Participant must be able to understand a written informed consent document and be willing to sign it\n* Participant must be assigned female at birth\n* Participant must have a Karnofsky performance score of greater than or equal to 70%\n* Women of child bearing potential must agree to avoid becoming pregnant through defined periods during the course of RT and must meet one of the following:\n\n  * Surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy\n  * Post-menopausal, defined as no menses for at least 12 months prior to the screening visit without alternative medical causation\n  * Agree to practice true abstinence from sexual intercourse\n  * Not in a sexual relationship in which the may become pregnant (i.e., same-sex relationship)\n  * If they are childbearing potential, agree to use at least one highly effective and at least one additional method of contraception.\n* For the first six participants only: Participant must have a Fitzpatrick Skin Tone Scale of 5 or 6\n\nExclusion Criteria:\n\n* Participants who have received prior radiation treatment to the affected breast.\n* Participants with a history of allergic reaction or hypersensitivity attributed to any tattoo ink\n* Participants with active chronic skin diseases such as psoriasis. Participants with inactive or controlled skin diseases are eligible for this study\n* Participants that are pregnant or breastfeeding. If a participant wishes to participate in this study, breastfeeding should be discontinued\n* Participants with a BMI greater than 44.5 as calculated within six months prior to the starting of the study. If there are multiple BMI measurements available in the chart, the most recent will be used to determine eligibility.",{"count":19,"type":20},[51],"The goal of this clinical trial is to learn if tattoos applied with Magic Ink is as safe as commercially available standard tattoo ink for the purpose of radiation in women with breast cancer undergoing radiation treatment. The main questions are:\n\n* Is the Magic Ink as safe as standard tattoo ink\n* Does Magic Ink continue to function and remain visible for radiation therapists during the treatment Participants will be consented and given a skin assessment. Once enrolled participants will be administered the Magic Ink tattoo instead of the standard tattoo ink in preparation for their radiation treatment. Participants will also complete a survey regarding body image. Skin assessment will occur again after the first week of radiation and at 3 months later. Throughout the radiation therapy the medical physicist will complete surveys about ease of set-up of the equipment.",[392,393,394,395],"Ductal Carcinoma in Situ","Stage I Breast Cancer","Stage II Breast Cancer","Stage III Breast Cancer","2025-09-12",{"date":130,"type":31},{"date":399,"type":31},"2025-08-18",{"date":401,"type":20},"2026-08-08",{"name":37,"class":38},{"id":404,"slug":405,"hasResults":11,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":4,"eligibilityCriteria":409,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":410,"targetDuration":4,"studyType":21,"phases":412,"briefSummary":413,"conditions":414,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":92},"100585919","addressing-social-determinants-of-health-among-metro-detroit-cancer-survivors-100585919","NCT06908629","Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors","Addressing Social Determinants of Health (SDOH) Among Metro Detroit Cancer Survivors: A Pilot Feasibility Study (The Resource Ready Study)","Inclusion Criteria:\n\n* 18 years or older\n* past or current cancer diagnosis\n* reside in metropolitan Detroit (Wayne, Oakland, Macomb counties)\n* English proficient\n* Actively receiving care through one of Karmano's Cancer Institute's outpatient clinics OR post treatment survivors in the Detroit Research on Cancer Survivors (ROCS) longitudinal cohort study who have reported past food insecurity and agreed to be contacted for further research\n\nExclusion Criteria:\n\n* none",{"count":411,"type":20},120,[51],"The goal of this screening study is to determine the feasibility of completing a social needs screening tool in participants who have a past or current cancer diagnosis and reside in Metro Detroit, Michigan. Main questions to answer are:\n\n* Can we have a completion rate of at least 80% of participants filling out the screening tool?\n* Can we determine procedures for patient referrals based on social needs\n* Can we implement brief interventions based on food access and digital inclusion (ensuring everyone has access to the digital technologies they need to participate in society)",[415,372,416,303,417],"Cancer","Gastrointestinal Cancers","Multiple Myeloma, Neoplasms","2025-08-25",{"date":420,"type":31},"2025-08-26",{"date":422,"type":31},"2024-09-03",{"date":424,"type":20},"2027-05",{"name":37,"class":38},""]